{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"025-572-203-367-955","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"025-572-203-367-955"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":8893,"type":"PATENT","title":"Imperial College Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":7925,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8215,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search applicants and Owners = \"Imperial College\", \"Imperial Coll* Sci* Tech* Medi*\", \"Imperial Innovations\", \"Imper* Colle* innova*\", \"Imperi* Innova*\",\"Imp* Col* Inno*\", \"Imperial College Of Science Technology\", \"Imperial Innovations Limited\", \" Imperial Innovations Ltd\", \"Imperial College Innovations Limited\".
Select more for logical variants
Add to collection
Select all the results in the collection and expand by simple families.
Add to collection
Total patents: 6345
Search Applicants and Owners separately: oregon uni*
Select more for logical variants.
Add to collection.
Select all patents in the collection and expand by simple families.
Add to collection. Total patents: 2661
Search applicants and Owners = \"Imperial College\", \"Imperial Coll* Sci* Tech* Medi*\", \"Imperial Innovations\", \"Imper* Colle* innova*\", \"Imperi* Innova*\",\"Imp* Col* Inno*\", \"Imperial College Of Science Technology\", \"Imperial Innovations Limited\", \" Imperial Innovations Ltd\", \"Imperial College Innovations Limited\".
Select more for logical variants
Add to collection
Select all the results in the collection and expand by simple families.
Add to collection
Total patents: 6345
Search Applicants and Owners separately: oregon uni*
Select more for logical variants.
Add to collection.
Select all patents in the collection and expand by simple families.
Add to collection. Total patents: 2661
a) decreasing calorie intake or food intake,
b) reducing weight gain, or inducing weight loss,
c) controlling any one or more of appetite, satiety and hunger,
d) maintaining desired body weight, a desired Body Mass Index, and/or a desired appearance and good health,
e) improving lipid profile,in a human subject comprising the administration of Peptide YY (PYY) or an agonist thereof and a Glucagon-like peptide-1 (GLP-1) or an agonist thereof, wherein the PYY or agonist thereof, and GLP-1 or agonist thereof are in a form suitable for peripheral administration, wherein the PYY or agonist thereof is for administration at a molar equivalent amount of a PYY3-36 dose of no more than 2.2 nmol per kg body weight of a subject, and wherein the subject desires to lose weight."],"number":16,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 16 wherein the PYY or agonist thereof and the GLP-1 or agonist thereof are formulated for administration simultaneously or sequentially."],"number":17,"annotation":false,"title":false,"claim":true},{"lines":["The method of any one of claims 16 or 17 wherein the PYY and the GLP-1 are formulated for administration via different routes."],"number":18,"annotation":false,"title":false,"claim":true},{"lines":["The method of any one of claims 16 to 18 wherein peripheral administration comprises subcutaneous, intravenous, intramuscular, intranasal, transdermal or sublingual administration."],"number":19,"annotation":false,"title":false,"claim":true},{"lines":["The method of any one of claims 16 to 19 wherein the PYY or agonist thereof formulated for peripheral administration comprises a formulation for peripheral administration of about 45 to about 135 pmol per kilogram body weight of the subject, or of about 72 pmol per kilogram body weight of the subject."],"number":20,"annotation":false,"title":false,"claim":true},{"lines":["The method of any one of claims 16 to 19 wherein the PYY or agonist thereof formulated for peripheral administration comprises a formulation suitable for administration in a multitude of doses, wherein each dose in the multitude of doses comprises administration of about 0.5 to about 135 pmol per kilogram of body weight at least about 30 minutes prior to a meal."],"number":21,"annotation":false,"title":false,"claim":true},{"lines":["The method of any one of claims 16 to 21 wherein the PYY or the agonist thereof is formulated for administration in an amount sufficient to decrease calorie intake for a period of about 2 to 12 hours."],"number":22,"annotation":false,"title":false,"claim":true},{"lines":["The method of any one of claims 16 to 19 wherein the PYY or agonist thereof is formulated for peripheral administration at a dose of 0.1 nmoles per kg body weight of the subject, 0.2 nmoles per kg body weight of the subject, 0.4 nmoles per kg body weight of the subject, 0.6 nmoles per kg body weight of the subject, 0.8 nmoles per kg body weight of the subject, 1.0 nmole per kg body weight of the subject, 1.2 nmoles per kg body weight of the subject, 1.4 nmoles per kg body weight of the subject, 1.6 nmoles per kg body weight of the subject, 1.8 nmoles per kg body weight of the subject, 2.0 nmoles per kg body weight of the subject, 2.2 nmoles per kg body weight of the subject."],"number":23,"annotation":false,"title":false,"claim":true},{"lines":["The method of any one of claims 16 to 23 wherein the PYY or agonist thereof is modified by one or more of amidation, glycosylation, acylation, sulfation, phosphorylation, cyclization, lipidization, or pegylation."],"number":24,"annotation":false,"title":false,"claim":true},{"lines":["The method of any one of claims 16 to 24 wherein the GLP-1 or agonist thereof comprises the amino acid sequence of GLP-1 (7-36) (SEQ ID NO:339) or a variant thereof that binds a GLP-1 receptor."],"number":25,"annotation":false,"title":false,"claim":true},{"lines":["The method of any one of claims 16 to 25 wherein the PYY is PYY3-36 or variant thereof."],"number":26,"annotation":false,"title":false,"claim":true},{"lines":["The method of any one of claims 16 to 24 wherein the GLP-1 agonist is extendin-4 or a derivative thereof that is a GLP-1 agonist."],"number":27,"annotation":false,"title":false,"claim":true},{"lines":["The method of any one of claims 16 to 27 suitable for administration in combination with amfepramone (diethylpropion), phentermine, mazindol, phenylpropanolamine, fenfluramine, dexfenfluramine, or fluoxetine."],"number":28,"annotation":false,"title":false,"claim":true},{"lines":["The method of any one of claims 16 to 28 wherein the PYY or agonist thereof is formulated for administration in an amount of from 1 to 100 nmols, from 2 to 90 nmols, from 5 to 80 nmols, or from 5 to 50 nmols."],"number":29,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}